Professor Graeme Milligan, co-founder of Caldan Therapeutics and colleague Dr Brian Hudson jointly author review publication

Professor Graeme Milligan, co-founder of Caldan Therapeutics and colleague Dr Brian Hudson have jointly authored a review entitled “FFA4/GPR120: Pharmacology and Therapeutic Opportunities” (Trends Pharmacol. Sci. 2017 Sep;38(9):809-821) PMID: 28734639. Substantial focus on the therapeutic potential of FFA4/GPR120 is currently directed towards metabolic diseases however high levels of expression of FFA4/GPR120 in the lung suggest utility in analysis of the potential therapeutic roles of FFA4/GPR120 ligands in both acute and chronic airway inflammatory conditions.